



Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature

Nemanja Rancic^{1*}, Viktorija Dragojevic-Simic¹, Neven Vavic², Aleksandra Kovacevic¹, Zoran Segrt³ and Natasa Djordjevic⁴

¹Centre for Clinical Pharmacology, Military Medical Academy Medical Faculty, University of Defence, Belgrade, Serbia, ²Solid Organ Transplantation Center, Military Medical Academy, Belgrade, Serbia, ³Management of the Military Medical Academy, Military Medical Academy Medical Faculty, University of Defence, Belgrade, Serbia, ⁴Department of Pharmacology and Toxicology, The Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

OPEN ACCESS

Edited by:

Rumen Stefanov,
Institute for Rare Diseases, Bulgaria

Reviewed by:

Martin Dlouhy,
University of Economics Prague,
Czech Republic
Enver Envi Roshi,
University of Medicine, Albania

*Correspondence:

Nemanja Rancic
nece84@hotmail.com

Specialty section:

This article was submitted
to Health Economics,
a section of the journal
Frontiers in Public Health

Received: 04 July 2016

Accepted: 23 August 2016

Published: 31 August 2016

Citation:

Rancic N, Dragojevic-Simic V,
Vavic N, Kovacevic A, Segrt Z and
Djordjevic N (2016) Economic
Evaluation of Pharmacogenetic
Tests in Patients Subjected
to Renal Transplantation:
A Review of Literature.
Front. Public Health 4:189.
doi: 10.3389/fpubh.2016.00189

Renal transplantation is the treatment of choice for the patients with end-stage renal failure. Genetic factors, among others, can influence variability in response to immunosuppressive drugs. Nowadays, due to restrictive health resources, the question arises whether routine pharmacogenetic analyses should be done in the renal transplant recipients or not. The aim of this literature review was to present the up-to-date information considering the economic feasibility of pharmacogenetic testing in patients subjected to renal transplantation. The organization United Network for Organ Sharing in the US estimated that total costs per renal transplant concerning these analyses were \$334,300 in 2014. Pharmacogenetic testing prior to treatment initiation could be helpful to predict and assess treatment response and the risks for adverse drug reactions. This kind of testing before treatment initiation seems to be one of the most promising applications of pharmacokinetics. Although pharmacogenetic tests were found to be a cost-effective or cost-saving strategy in many cases, some authors represent another opinion. However, if the real costs of renal transplantation are recognized, the application of these tests in the standard daily practice could be considered more realistic, which additionally emphasizes the importance of future studies assessing their cost effectiveness.

Keywords: health economics, genetic polymorphisms, renal transplantation, pharmacogenetic tests, immunosuppressive drugs

INTRODUCTION

End-stage renal disease is the last stage of the chronic renal disease. The most common causes of end-stage renal disease are diabetes and high blood pressure (1–3). In the general population, the prevalence of chronic renal disease varies approximately from 7 to 20% (4–8). Dialysis (hemodialysis and peritoneal dialysis) and renal transplantation are the treatments for the patients with end-stage renal failure. Renal transplantation is the treatment of choice for these patients since survival rate and quality of life are better in comparison to patients who are subjected to dialysis (9, 10).

According to US statistics, chronic kidney disease afflicted up to 20 million people, while more than 871,000 of patients were being treated for end-stage renal diseases in 2009 (11, 12). Also, 17,107

renal transplants were performed in 2014. Moreover, 100,791 people are currently estimated to be waiting for renal transplants (13). Pre-end-stage renal disease entails a cost in excess of \$26,000 per patient per year (12). The World Health Organization, as the leading authority, is seriously concerned about these figures.

The major problems in renal transplantation are: the shortage of donors, adequate immunosuppression, allograft dysfunction and rejection, adverse reactions to drugs, therapeutic drug monitoring (TDM), restricted health resources, etc. However, the problems of greatest concern are the prevention of graft rejection and chronic toxicity of immunosuppressants due to their inadequate levels in the plasma. The inter- and intraindividual variability in response to immunosuppressive drugs is well known (14, 15). Gender, age, body mass index, hematocrit, diabetes status, liver dysfunction, drug interactions, etc., can also influence the variability in response to these drugs among patients (14, 16). In addition, genetic factors are likely to play a major role as well (17, 18).

Personalized medicine refers to the application of patient-specific profiles (incorporating genetic and genomic data) in order to assess individual risks and tailor prevention and disease-management strategies (19, 20). Therefore, a better control of immunosuppression should be achieved by pharmacogenetic testing (21).

Current recommended immunosuppression protocols in the patients subjected to renal transplantation include a combination of calcineurin inhibitors (tacrolimus or cyclosporine) and antiproliferative agents (mycophenolate mofetil or azathioprine), with and without regimens of corticosteroids (18, 22, 23). Tacrolimus as the first-line treatment is recommended by the Kidney Disease Improving Global Outcomes Transplant Work Group (KDIGO) (23). Mammalian target of rapamycin (mTOR) inhibitors (everolimus or sirolimus) should be used instead of calcineurin inhibitors but only after the graft function has been established and surgical wounds have healed (23). Induction therapy (interleukin 2 receptor antagonists) is used in high-immunological risk renal transplant recipients.

Gene polymorphism as a significant factor contributes to the variability in pharmacokinetics and pharmacodynamics of immunosuppressive drugs, which may result in their toxicity and/or lack of efficacy (14, 15, 24, 25). Therefore, pharmacogenetic analyses could be very important for immunosuppressive drug therapy. However, due to the restriction of health resources, the question arises whether renal transplantation management should include routine pharmacogenetic testing.

The aim of our study was to determine the economic feasibility of pharmacogenetic analyses in patients subjected to renal transplantation based on a review of relevant literature.

THE IMPACT OF GENETIC POLYMORPHISMS ON THE METABOLISM AND TRANSPORT OF IMMUNOSUPPRESSIVE DRUGS

The TDM of immunosuppressive drugs helps the determination of suitable dose, and the trial and error approach to dosing is still a common everyday practice. Nowadays, the challenge is to

combine pharmacogenetic with pharmacokinetic information in order to provide patients with the most suitable treatment.

Many pharmacogenetic studies have been conducted to evaluate the importance of genetic polymorphism for tacrolimus and cyclosporine therapy success, mostly in regard to CYP3A4/5 and P-glycoprotein (P-gp). The most prominent gene-dependent effect on tacrolimus pharmacokinetics has been observed for CYP3A5 (26). CYP3A5 activity differs significantly among individuals, which is mainly due to its genetic polymorphism: those who have at least one wild-type allele (*CYP3A5*1*) are denoted as expressors, and homozygote carriers of non-functional alleles, such as *CYP3A5*3*, as non-expressors (27). Numerous studies on tacrolimus pharmacokinetics in transplant recipients consistently reported that carriers of *CYP3A5*3*/**3* genotype require significantly lower doses for both induction and the maintenance phase of the therapy (28–38). Similar effects of CYP3A5 polymorphism on cyclosporine levels have been detected, but the reports remained largely inconsistent (29, 37, 39–41).

Although wide interindividual variations in CYP3A4 levels have been described (42), only few gene polymorphisms have been associated with altered *in vivo* enzyme activity (43, 44). In renal transplant patients, significantly lower daily tacrolimus dose requirements were observed in carriers of *CYP3A4*18* and **22* alleles (41, 45–47), especially in CYP3A5 non-expressors (48–50). The same, but usually less, pronounced effect was detected in transplant recipients on cyclosporine therapy (40, 47, 48). On the other hand, *CYP3A4*1B* have been associated with higher tacrolimus dose requirements (51, 52), but the conclusions remained arguable, mainly due to the strong linkage disequilibrium between this *CYP3A4* allele and fully functional *CYP3A5*1* (29).

P-glycoprotein is an efflux transporter involved in elimination and permeability restriction of numerous endogenous and xenobiotic compounds, including calcineurin inhibitors (53, 54). It is encoded by the highly polymorphic *ABCB1* (*MDR1*) gene, with more than 250 non-synonymous single nucleotide polymorphisms (SNPs) described so far (54). Of those, the most frequent and thus most extensively studied are 1236C > T, 2677G > T/A, and 3435C > T (53, 54). In the renal transplant recipients that do not express CYP3A5, 1236–2677–3435 TTT–TTT diplotype was highly associated with lower tacrolimus dose requirements (38), and similar effect was observed when individual *ABCB1* polymorphisms were considered (55–57). In patients on cyclosporine therapy, significantly higher daily dose requirements were found in 2677GG and 3435CC genotype carriers (58, 59). However, there are studies that failed to find any significant association between pharmacogenetics of P-gp and pharmacokinetics of calcineurin inhibitors (60–62); therefore, the proposed relationship is still considered controversial.

Inhibitors of mTOR are substrates for CYP3A4/5 and CYP2C8 enzymes and P-gp (63). However, pharmacogenetic studies in regard to sirolimus and everolimus treatment are scarce and with conflicting results. In renal transplant recipients, significantly higher sirolimus dose requirements were observed in carriers of *CYP3A4*1B* allele or in the absence of *CYP3A5*3*, while *ABCB1* polymorphism did not affect drug pharmacokinetics (64–66). The effect of *CYP3A5*3* on everolimus was investigated, but not detected (67, 68).

Based on a considerable body of evidence in favor of clinically relevant genotype–phenotype association, a guideline for *CYP3A5* genotype and tacrolimus dosing was published (69). In regard to other calcineurin and mTOR inhibitors and their disposition-related genes, there are currently not enough data to support routine pharmacogenetic testing (70).

Azathioprine is a precursor of 6-mercaptopurine (6-MP), further metabolized to active thioguanine nucleotide (TGN) metabolites through a multi-step process (71, 72). Glutathione S-transferase has been implicated in the formation of 6-MP, which is then inactivated in the liver by highly polymorphic thiopurine S-methyltransferase (TPMT), as well as by xanthine oxidase (73). Heterozygous and homozygous carriers of non-functional *TPMT* alleles (mainly *2, *3A, *3B, *3C, and *4) have low and deficient enzyme activity, respectively, and are at significantly higher risk of adverse drug reactions to azathioprine (73–76). Thus, the routine genotyping for *TPMT* polymorphisms prior to the initiation of the therapy has become a cornerstone of thiopurines-based treatment (77).

Mycophenolat mofetil is another prodrug, which requires enzymatic hydrolysis for activation (78). Mycophenolic acid then undergoes further biotransformation, which includes glucuronidation as the major metabolic pathway. Several uridine 5′-diphospho glucuronosyl transferases (UGTs) are involved in the process. However, UGT1A9 is of special importance, as certain SNPs of its coding gene, as well as of the genes coding for drug transporters (such as *SLCO1B1*), lead to a significantly lower drug exposure and a higher risk of acute transplant rejection (79, 80). In addition, the gene coding for inosine monophosphate dehydrogenase (*IMPDH*), the target of mycophenolic acid, is also polymorphic, and the association of certain *IMPDH* SNPs with the immunosuppressive response were reported (81). However, the data on the impact of genetics on the drug efficacy and safety are still conflicting (70, 78). Therefore, currently, there are no recommendations for routine pharmacogenetic testing in regard to mycophenolat mofetil therapy.

In regard to the use of biologic agents and corticosteroids in induction and maintenance therapy, no evidence showing the association between genetic polymorphisms and their pharmacokinetics or pharmacodynamics was found in the literature (82).

THE ECONOMIC EVALUATION OF RENAL TRANSPLANTATION

The history of health economics in recent decades (83) teaches us that the burden of non-communicable “prosperity” illnesses is among the top causes of growing costs of health care (84). This landscape of medical care spending has evolved considerably across the Globe with developing and emerging economies taking ever larger share of global expenditure on health (85). This fact is taking its toll since the Third World nations are facing double burden: the old unresolved pool of infectious diseases and another rapidly expanding one attributable to the non-communicable diseases (NCD) (86). Coping with the challenges outsourcing from cancer, diabetes, fertility issues, mental


disorders, and ultimately renal failure, thus, is made substantially more difficult. These systems were traditionally shaped to combat acute communicable diseases and injuries at the first place (87). Now they face chronic illnesses, which are far more demanding in terms of social capital and medical resources that need to be devoted (88). Among the few bright success stories in lessening the grip of major NCDs are certainly the BRICS nations (89). Such change of morbidity has clearly reflected on the demand for pharmaceuticals and national spending on medicines in a large number of countries (90, 91). In case of immunosuppressants used in renal transplantation procedures, this growth was significant both in prescription and value-based terms (92). Surgical services, imaging diagnostics, and home-based care, next to dialysis, should not be forgotten as major cost drivers in terminal renal failure treatment.

Nowadays, a renal transplantation is considered the treatment of choice for many people with severe chronic kidney disease, but there is a shortage of organs available for donation. Many people who are candidates for kidney transplantation are just put on a transplant list to wait for an available organ. However, the waiting time on the list may vary considerably.

The costs of renal transplantation include transplant evaluation and testing, transplant surgery, follow-up care, and medication. After a renal transplantation, patients will need several drugs, including immunosuppressants, to sustain the transplanted kidney. Costs per one transplant patient in Serbia for a 10-year period were calculated to be €48,949 (93). On the other hand, according to the US United Network for Organ Sharing (UNOS), the first year billed charges for a kidney transplant are more than \$262,000 (94). The total monthly costs of Cellcept®, Prograf®, Prednisone®, and Myfortic® are approximately \$1,064, \$1,340, \$12, and \$806, respectively. The 2-year costs of four different immunosuppressive strategies (sirolimus, everolimus, cyclosporine, or tacrolimus) have been shown to vary between €26,732 and €49,978 (95). Therefore, in the time of restricted health resources, the choice of therapy is very important.

Renal transplantation costs differ significantly worldwide. For example, the total cost of renal transplantation procedure in Iran was \$9,224 (96). The immunosuppressive therapy accounted for 65.8% (\$6,076), only in the first year. The transplantation procedure costs were \$2,048, while organ procurement was about \$1,100. On the other hand, the total costs of the first year after transplantation in Sudan were US\$14,825 and after that approximately US\$10,651 (97). The renal transplant cost estimate in India was about US\$70,000 for laparoscopic kidney transplantation, while open nephrectomy costs were US\$100,000 (98). In the US, laparoscopic kidney transplantation and open nephrectomy cost approximately US\$300,000 and US\$450,000, respectively.

Cost estimates of UNOS per renal transplant concerning 30 days pre-transplantation, procurement, hospital transplant admission, physician services during transplant, 180-days post-transplant, and administration of immunosuppressants in 2011 and 2014 in the US are represented in **Figure 1** (99). The total costs were \$262,900 and \$334,300 in 2011 and 2014, respectively (99–101).



THE ECONOMIC EVALUATION OF PHARMACOGENETIC TESTS

Pharmacogenetic testing prior to the treatment initiation could be helpful to assess both the risks of adverse drug reactions and treatment response (21, 102). Moreover, pharmacogenetics-based testing before treatment initiation seems to be one of the most promising applications of drug pharmacokinetics.

The cost effectiveness of genotyping prior to the therapy with some drugs, such as abacavir, allopurinol, carbamazepine, clopidogrel, and irinotecan, indicates that genotyping was justified when it was performed on a large numbers of patients. However, evaluation of cost effectiveness of genotyping prior to the use of immunosuppressive drugs has not been performed yet.

Provenzani et al. concluded that, considering the relatively high costs of pharmacogenetic tests and availability of TDM, the genotyping of all transplant patients is not affordable in many countries (103). This situation may change in the near future since studies on pharmacogenetics would produce valuable data, and the improvements in the genotyping analyses will decrease the costs associated with this type of tests. However, prospective

clinical studies must show that genotype determination before transplantation allows for the better use of given drugs and improves their safety and clinical efficacy. Currently, genetic tests determining a patient's CYP2D6 and CYP2C19 polymorphisms cost from \$350 to \$400, not including the markup and some other costs associated with the test. Moreover, most genetic tests cost a few hundred dollars at the moment, but they are estimated to become less expensive in the future (104–106). However, to justify the costs of genetic testing, genotypic analyses have to demonstrate their ability to significantly improve transplant patient outcomes and show cost savings.

The pharmacogenetic tests prior to the treatment with azathioprine represent a good example of saving money. The cost-effectiveness model for azathioprine, based on parameters collected for TPMT genotyping costs, estimates for frequency of TPMT deficiency, rates of thiopurine-mediated myelosuppression in TPMT-deficient individuals, and myelosuppression-related hospitalization costs, established that TPMT testing in all patients had a favorable cost-effectiveness ratio (107). The costs of a genotype test were estimated on about \$NZ30 (€18.90) (108). In another study, it was estimated that costs of the TPMT screening

(genotype) were \$510.06 (109). These authors concluded that the least costly treatment strategy was TPMT screening, with 1-year costs saving per patient of \$3,281. The mean calculated cost per life year, gained by TPMT genotyping in all patients in the four studied countries (Germany, Ireland, Netherlands, and the United Kingdom), was €2,100, based on genotyping costs of €150 per patient (107).

Thervet et al. have recommended a successful protocol of tacrolimus starting dose determined by patient's genotype: CYP3A5*3*3 are to be given 0.15 mg/kg/day, while CYP3A5*1*1 or *1*3 expressers should be treated with 0.30 mg/kg/day (110). On the base of this protocol, in the group receiving the adapted dose, a higher proportion of patients had values within the targeted C_0 on day 3 after the initiation of tacrolimus. Namely, they required fewer dose modifications while the targeted C_0 was achieved by 75% of these patients more rapidly. This pharmacogenetic test prior to tacrolimus initiation could be helpful to reduce the risks of adverse drug reactions due to the patient overexposure, as well as to reduce the costs due to the faster achievement of the optimal tacrolimus concentrations.

The substantial increase of health expenditure, due to the rapid population growth and aging became a great concern for governments all over the world (111, 112). On the one hand, while extensive literature on the determinants of health expenditure in the Organization for economic co-operation and development (OECD) countries can be found, that is not the case with the situation in developing countries (101). Literature data show great variations between countries concerning health expenditure, since gross domestic product share ranges from 5 to 15%. For example, health expenditure per capita of US\$9,715 in Norway is the biggest, while US\$13 in the Central African Republic is the smallest.

There are many factors that account for the enormous costs of pharmacogenetic analyses. Devices themselves, with the current

price of about \$10,000, together with trained staff necessary to perform analyses, are the most expensive ones. It is obvious that these costs are high even for the developed countries, whereas for the developing countries, they are unaffordable for the time being (113).

CONCLUSION

Due to the lack of appropriate cost-effectiveness studies, and the availability of TDM analyses, from an economic point of view, we could neither recommend nor discourage the use of pharmacogenetic tests as a routine clinical practice in the everyday treatment of renal transplant patients. Future recommendations will depend on robust clinical evidence regarding pharmacogenetic test efficacy and precise costs concerning renal transplantation.

AUTHOR CONTRIBUTIONS

NR coordinated the teamwork of coauthors, wrote the paper, and searched for literature. VD-S assisted with the writing of the article, searched for literature, and had done the critical revision of the text. NV assisted with the writing of the article and searched for literature. AK assisted with the writing of the article and searched for literature. ZS assisted with the writing of the article and searched for literature. ND assisted with the writing of the article, searched for literature, and had done the critical revision of the text. All authors read and approved the final manuscript.

FUNDING

The authors would like to express their gratitude to the Ministry of Science and Education of the Republic of Serbia for Grants No. 175014, 175007, 175093, and 175056, out of which this research project was partially financed.

REFERENCES

- Ghony TA, Farag SE, Soliman SA, El-okely A, El-hendy Y. Epidemiology and risk factors of chronic kidney disease in the El-Sharkia Governorate, Egypt. *Saudi J Kidney Dis Transpl* (2016) 27(1):111–7. doi:10.4103/1319-2442.174137
- Nasri H, Rafieian-Kopaei M. Diabetes mellitus and renal failure: prevention and management. *J Res Med Sci* (2015) 20(11):1112–20. doi:10.4103/1735-1995.172845
- Verma A, Vyas S, Agarwal A, Abbas S, Agarwal DP, Kumar R. Diabetic kidney disease and hypertension: a true love story. *J Clin Diagn Res* (2016) 10(3):OC11–3. doi:10.7860/JCDR/2016/18806.7511
- Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. *Am J Kidney Dis* (2008) 51(4 Suppl 2):S13–20. doi:10.1053/j.ajkd.2007.12.016
- Chen N, Wang W, Huang Y, Shen P, Pei D, Yu H, et al. Community-based study on CKD subjects and the associated risk factors. *Nephrol Dial Transplant* (2009) 24(7):2117–23. doi:10.1093/ndt/gfn767
- Cepoi V, Onofriescu M, Segall L, Covic A. The prevalence of chronic kidney disease in the general population in Romania: a study on 60,000 persons. *Int Urol Nephrol* (2012) 44(1):213–20. doi:10.1007/s11255-011-9923-z
- Browne GM, Eustace JA, Fitzgerald AP, Lutonski JE, Perry IJ. Prevalence of diminished kidney function in a representative sample of middle and older age adults in the Irish population. *BMC Nephrol* (2012) 13:144. doi:10.1186/1471-2369-13-144
- Ponte B, Pruijm M, Marques-Vidal P, Martin PY, Burnier M, Paccaud F, et al. Determinants and burden of chronic kidney disease in the population-based CoLaus study: a cross-sectional analysis. *Nephrol Dial Transplant* (2013) 28(9):2329–39. doi:10.1093/ndt/gft206
- Miners AH, Yao G, Raftery J, Taylor RS. Economic evaluations of calcineurin inhibitors in renal transplantation: a literature review. *Pharmacoeconomics* (2007) 25(11):935–47. doi:10.2165/00019053-200725110-00004
- UpToDate, Berns JS. *Patient Information: Dialysis or Kidney Transplantation – Which is Right for Me? (Beyond the Basics)*. (2016). Available from: <http://www.uptodate.com/contents/dialysis-or-kidney-transplantation-which-is-right-for-me-beyond-the-basics>
- National Institute of Diabetes and Digestive and Kidney Diseases. *Kidney Disease Statistics for the United States*. (2012). Available from: <http://www.niddk.nih.gov/health-information/health-statistics/Pages/kidney-disease-statistics-united-states.aspx#16>
- Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. *J Am Soc Nephrol* (2004) 15(5):1300–6. doi:10.1097/01.ASN.0000125670.64996.BB
- The National Kidney Foundation. *Organ Donation and Transplantation Statistics*. (2016). Available from: <https://www.kidney.org/news/newsroom/factsheets/Organ-Donation-and-Transplantation-Stats>

14. Vavic N, Rancic N, Dragojevic-Simic V, Draskovic-Pavlovic B, Bokonjic D, Ignjatovic L, et al. The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: retrospective study. *Eur J Drug Metab Pharmacokinet* (2014) 39(4):243–53. doi:10.1007/s13318-013-0168-3
15. Rancic N, Dragojevic-Simic V, Vavic N, Kovacevic A, Segrt Z, Draskovic-Pavlovic B, et al. Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: the influence of gender and comedication. *Vojnosanit Pregl* (2015) 72(9):813–22. doi:10.2298/VSP140905005R
16. Rančić NK, Vavić NN, Kovačević AM, Mikov MM, Dragojević-Simić VM. Drug-drug interactions of tacrolimus. *Hosp Pharmacol* (2015) 2(3):291–6.
17. Vavić N, Rančić N, Cikota-Aleksić B, Magić Z, Cimeša J, Obrenčević K, et al. The distribution of genetic polymorphism of CYP3A5, CYP3A4 and ABCB1 in patients subjected to renal transplantation. *Vojnosanit Pregl* (2016) 73(7):663–7. doi:10.2298/VSP150505016V
18. Birdwell K. Role of pharmacogenomics in dialysis and transplantation. *Curr Opin Nephrol Hypertens* (2014) 23(6):570–7. doi:10.1097/MNH.0000000000000065
19. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. *BMC Med Ethics* (2013) 14:55. doi:10.1186/1472-6939-14-55
20. Frueh FW, Gurwitz D. From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. *Pharmacogenomics* (2004) 5(5):571–9. doi:10.1517/14622416.5.5.571
21. Vegter S, Jansen E, Postma MJ, Boersma C. Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. *Drug Dev Res* (2010) 71:492–501. doi:10.1002/ddr.20424
22. Karam S, Wali RK. Current state of immunosuppression: past, present, and future. *Crit Rev Eukaryot Gene Expr* (2015) 25(2):113–34. doi:10.1615/CritRevEukaryotGeneExpr.2015011421
23. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant* (2009) 9(Suppl 3):S1–155. doi:10.1111/j.1600-6143.2009.02834.x
24. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. *Pharmacol Rev* (2011) 63(2):437–59. doi:10.1124/pr.110.003533
25. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. *Pharmacogenomics J* (2013) 13(1):1–11. doi:10.1038/tj.2012.45
26. Dai Y, Hebert ME, Isoherranen N, Davis CL, Marsh C, Shen DD, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. *Drug Metab Dispos* (2006) 34(5):836–47. doi:10.1124/dmd.105.008680
27. Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. *Pharmacogenet Genomics* (2012) 22(7):555–8. doi:10.1097/FPC.0b013e328351d47f
28. Vannaprasaht S, Reungjui S, Supanya D, Sirivongs D, Pongskul C, Avihingsanon Y, et al. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation. *Clin Ther* (2013) 35(11):1762–9. doi:10.1016/j.clinthera.2013.08.019
29. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. *Clin Pharmacol Ther* (2003) 74(3):245–54. doi:10.1016/S0009-9236(03)00168-1
30. Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Habuchi T, et al. Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation. *Int J Mol Sci* (2015) 16(1):1840–54. doi:10.3390/ijms16011840
31. Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, et al. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase. *Pharmacogenomics* (2015) 16(18):2045–54. doi:10.2217/pgs.15.138
32. Alvarez-Elias AC, García-Roca P, Velásquez-Jones L, Valverde S, Varela-Fascinetto G, Medeiros M. CYP3A5 genotype and time to reach tacrolimus therapeutic levels in renal transplant children. *Transplant Proc* (2016) 48(2):631–4. doi:10.1016/j.transproceed.2016.02.024
33. Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. *Aliment Pharmacol Ther* (2004) 20(6):593–9. doi:10.1111/j.1365-2036.2004.02124.x
34. Yousef AM, Qosa H, Bulatova N, Abuhaliema A, Almadhoun H, Khayyat G, et al. Effects of genetic polymorphism in CYP3A4 and CYP3A5 genes on tacrolimus dose among kidney transplant recipients. *Iran J Kidney Dis* (2016) 10(3):156–63.
35. Luo X, Zhu LJ, Cai NF, Zheng LY, Cheng ZN. Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*3) genotype in Chinese renal transplant recipients. *Acta Pharmacol Sin* (2016) 37(4):555–60. doi:10.1038/aps.2015.163
36. Prytula AA, Cransberg K, Bouts AH, van Schaik RH, de Jong H, de Wildt SN, et al. The effect of weight and CYP3A5 genotype on the population pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients. *Clin Pharmacokinet* (2016). doi:10.1007/s40262-016-0390-7
37. Monostory K, Tóth K, Kiss Á, Háfra E, Csikány N, Paulik J, et al. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. *Br J Clin Pharmacol* (2015) 80(6):1429–37. doi:10.1111/bcp.12747
38. Li JL, Liu S, Fu Q, Zhang Y, Wang XD, Liu XM, et al. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tacrolimus trough concentrations in early postrenal transplant recipients. *Pharmacogenomics* (2015) 16(12):1355–65. doi:10.2217/pgs.15.78
39. Qiu F, He XJ, Sun YX, Li-Ling J, Zhao LM. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. *Pharmacol Rep* (2011) 63(3):815–25. doi:10.1016/S1734-1140(11)70594-1
40. Tao XR, Xia XY, Zhang J, Tong LY, Zhang W, Zhou X, et al. CYP3A4*18B and CYP3A5*3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. *Eur J Pharm Sci* (2015) 76:238–44. doi:10.1016/j.ejps.2015.05.011
41. Li DY, Teng RC, Zhu HJ, Fang Y. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. *Int J Clin Pharmacol Ther* (2013) 51(6):466–74. doi:10.5414/CP201836
42. Westlind A, Löfberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. *Biochem Biophys Res Commun* (1999) 259(1):201–5. doi:10.1006/bbrc.1999.0752
43. Kang YS, Park SY, Yim CH, Kwak HS, Gajendrarao P, Krishnamoorthy N, et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. *Clin Pharmacol Ther* (2009) 85(3):312–8. doi:10.1038/clpt.2008.215
44. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. *Pharmacogenomics J* (2011) 11(4):274–86. doi:10.1038/tj.2010.28
45. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. *Clin Chem* (2011) 57(11):1574–83. doi:10.1373/clinchem.2011.165613
46. Pallet N, Jannot AS, El Bahri M, Etienne I, Buchler M, de Ligny BH, et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. *Am J Transplant* (2015) 15(3):800–5. doi:10.1111/ajt.13059
47. Moes DJ, Swen JJ, van der Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation. *CPT Pharmacometrics Syst Pharmacol* (2014) 3:e100. doi:10.1038/psp.2013.78
48. Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. *Pharmacogenomics* (2011) 12(10):1383–96. doi:10.2217/pgs.11.90
49. Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. *Ther Drug Monit* (2013) 35(5):608–16. doi:10.1097/FTD.0b013e318296045b

50. de Jonge H, Elens L, de Loor H, van Schaik RH, Kuypers DR. The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. *Pharmacogenomics J* (2015) 15(2):144–52. doi:10.1038/tpj.2014.49
51. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. *Transpl Int* (2012) 25(4):471–80. doi:10.1111/j.1432-2277.2012.01446.x
52. Tavira B, Coto E, Diaz-Corte C, Ortega F, Arias M, Torres A, et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. *Clin Chem Lab Med* (2011) 49(5):825–33. doi:10.1515/CCLM.2011.143
53. Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. *Clin Pharmacokinet* (2015) 54(7):709–35. doi:10.1007/s40262-015-0267-1
54. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). *Pharmacogenet Genomics* (2011) 21(3):152–61. doi:10.1097/FPC.0b013e3283385a1c
55. Li D, Gui R, Li J, Huang Z, Nie X. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. *Transplant Proc* (2006) 38(9):2850–2. doi:10.1016/j.transproceed.2006.08.089
56. Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. *Transplant Proc* (2009) 41(3):840–2. doi:10.1016/j.transproceed.2009.01.050
57. Ciftci HS, Ayna TK, Caliskan YK, Guney I, Bakkaloglu H, Nane I, et al. Effect of MDR1 polymorphisms on the blood concentrations of tacrolimus in Turkish renal transplant patients. *Transplant Proc* (2013) 45(3):895–900. doi:10.1016/j.transproceed.2013.02.055
58. Sharaki O, Zeid M, Moez P, Zakaria NH, Nassar E. Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. *Mol Biol Rep* (2015) 42(1):105–17. doi:10.1007/s11033-014-3747-8
59. Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, et al. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients. *Transplant Proc* (2006) 38(5):1290–2. doi:10.1016/j.transproceed.2006.02.079
60. Mourad M, Mourad G, Wallemacq P, Garrigue V, Van Bellingen C, Van Kerckhove V, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. *Transplantation* (2005) 80(7):977–84. doi:10.1097/01.TP.0000174131.47469.D2
61. Rong G, Jing L, Deng-Qing L, Hong-Shan Z, Shai-Hong Z, Xin-Min N. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. *Transplant Proc* (2010) 42(9):3455–8. doi:10.1016/j.transproceed.2010.08.063
62. Tada H, Tsuchiya N, Satoh S, Kagaya H, Li Z, Sato K, et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. *Transplant Proc* (2005) 37(4):1730–2. doi:10.1016/j.transproceed.2005.02.073
63. Klumpen HJ, Beijnen JH, Gurney H, Schellens JH. Inhibitors of mTOR. *Oncologist* (2010) 15(12):1262–9. doi:10.1634/theoncologist.2010-0196
64. Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. *Am J Transplant* (2005) 5(3):595–603. doi:10.1111/j.1600-6143.2005.00745.x
65. Miao LY, Huang CR, Hou JQ, Qian MY. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. *Biopharm Drug Dispos* (2008) 29(1):1–5. doi:10.1002/bdd.577
66. Le Meur Y, Djebli N, Szelag JC, Hoizey G, Toupance O, Rérolle JP, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. *Clin Pharmacol Ther* (2006) 80(1):51–60. doi:10.1016/j.cpt.2006.03.012
67. Picard N, Rouguieg-Malki K, Kamar N, Rostaing L, Marquet P. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. *Transplantation* (2011) 91(6):652–6. doi:10.1097/TP.0b013e31820ae4ac
68. Moes DJ, Press RR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. *Clin Pharmacokinet* (2012) 51(7):467–80. doi:10.2165/11599710-000000000-00000
69. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. *Clin Pharmacol Ther* (2015) 98(1):19–24. doi:10.1002/cpt.113
70. Zaza G, Granata S, Tomei P, Dalla Gassa A, Lupo A. Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in “omics” medicine. *Int J Mol Sci* (2015) 16(2):4281–305. doi:10.3390/ijms16024281
71. Zaza G, Cheok M, Krynetskaia N, Thorn C, Stocco G, Hebert JM, et al. Thiopurine pathway. *Pharmacogenet Genomics* (2010) 20(9):573–4. doi:10.1097/FPC.0b013e328334338f
72. Al-Judaibi B, Schwarz UI, Huda N, Dresser GK, Gregor JC, Ponich T, et al. Genetic predictors of azathioprine toxicity and clinical response in patients with inflammatory bowel disease. *J Popul Ther Clin Pharmacol* (2016) 23(1):e26–36.
73. Kurzawski M, Dziewanowski K, Gawronska-Szkwarz B, Domański L, Drożdżik M. The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients. *Ther Drug Monit* (2005) 27(4):435–41. doi:10.1097/01.ftd.0000164393.09402.c9
74. Formea CM, Myers-Huentelman H, Wu R, Crabtree J, Fujita S, Hemming A, et al. Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients. *Am J Transplant* (2004) 4(11):1810–7. doi:10.1111/j.1600-6143.2004.00575.x
75. Song DK, Zhao J, Zhang LR. TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment. *J Clin Pharm Ther* (2006) 31(6):627–35. doi:10.1111/j.1365-2710.2006.00775.x
76. Chrzanowska M, Kurzawski M, Drożdżik M, Mazik M, Oko A, Czekalski S. Thiopurine S-methyltransferase phenotype-genotype correlation in hemodialyzed patients. *Pharmacol Rep* (2006) 58(6):973–8.
77. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. *Clin Pharmacol Ther* (2011) 89(3):387–91. doi:10.1038/clpt.2010.320
78. Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE. PharmGKB summary: mycophenolic acid pathway. *Pharmacogenet Genomics* (2014) 24(1):73–9. doi:10.1097/FPC.000000000000010
79. van Schaik RH, van Ageren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, et al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. *Clin Pharmacol Ther* (2009) 86(3):319–27. doi:10.1038/clpt.2009.83
80. Picard N, Yee SW, Woillard JB, Lebranchu Y, Le Meur Y, Giacomini KM, et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. *Clin Pharmacol Ther* (2010) 87(1):100–8. doi:10.1038/clpt.2009.205
81. Medicines and Medical Devices Agency of Serbia. *Simulect, Summary Characteristic of Product*. (2011). Available from: <http://www.alims.gov.rs/ciril/files/lekovi/smpc/515-01-6980-10-001.pdf>
82. Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der Werf M, Vulto AG, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. *Pharmacogenet Genomics* (2009) 19(8):626–34. doi:10.1097/FPC.0b013e32832f5f1b
83. Jakovljevic M, Ogura S. Health economics at the crossroads of centuries – from the past to the future. *Front Public Health* (2016) 4:115. doi:10.3389/fpubh.2016.00115
84. Jakovljevic MB, Milovanovic O. Growing burden of non-communicable diseases in the emerging health markets: the case of BRICS. *Front Public Health* (2015) 3:65. doi:10.3389/fpubh.2015.00065

85. Jakovljevic M, Getzen TE. Growth of global health spending share in low and middle income countries. *Front Pharmacol* (2016) 7:21. doi:10.3389/fphar.2016.00021
86. Jakovljevic M, Groot W, Souliotis K. Editorial: health care financing and affordability in the emerging global markets. *Front Public Health* (2016) 4:2. doi:10.3389/fpubh.2016.00002
87. Rancic N, Jakovljevic MM. Long term health spending alongside population aging in N-11 emerging nations. *East Eur Bus Econ J* (2016) 2(1):2–26.
88. Jakovljevic MB. BRIC's growing share of global health spending and their diverging pathways. *Front Public Health* (2015) 3:135. doi:10.3389/fpubh.2015.00135
89. Jakovljevic M, Potapchik E, Popovich L, Barik D, Getzen T. Evolving health expenditure landscape of the BRICS nations and projections to 2025. *Health Econ* (2016) (in press).
90. Jakovljevic M, Lazarevic M, Milovanovic O, Kanjevac T. The new and old Europe: east-west split in pharmaceutical spending. *Front Pharmacol* (2016) 7:18. doi:10.3389/fphar.2016.00018
91. Jakovljevic MB, Souliotis K. Pharmaceutical expenditure changes in Serbia and Greece during the global economic recession. *SEEJPH* (2016) 5:1–17. doi:10.4119/UNIBI/SEEJPH-2016-101
92. Jakovljevic MB, Djordjevic N, Jurisevic M, Jankovic S. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. *Expert Rev Pharmacoecon Outcomes Res* (2015) 15(3):521–30. doi:10.1586/14737167.2015.1003044
93. Perović S, Janković S. Renal transplantation vs. hemodialysis: cost-effectiveness analysis. *Vojnosanit Pregl* (2009) 66(8):639–44. doi:10.2298/VSP0908639P
94. California Pacific Medical Center, part of the Sutter Health network. *Costs and Financing of Kidney Transplant*. (2014). Available from: http://www.cpmc.org/advanced/kidney/patients/topics/financing_kidney_transplant.html
95. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. *Health Technol Assess* (2005) 9(21):1–179. doi:10.3310/hta9210
96. Nourbala MH, Einollahi B, Kardavani B, Khoddami-Vishte HR, Assari S, Mahdavi-Mazdeh M, et al. The cost of kidney transplantation in Iran. *Transplant Proc* (2007) 39(4):927–9. doi:10.1016/j.transproceed.2007.03.056
97. Elsharif ME, Elsharif EG, Gadour WH. Costs of hemodialysis and kidney transplantation in sudan: a single center experience. *Iran J Kidney Dis* (2010) 4:282–4.
98. Forerunners Health Care. *Kidney Transplant in India*. (2016). Available from: <http://www.forerunnershealthcare.com/kidney-transplant-India-low-cost-advantages.html>
99. National Foundation for Transplants. *How Much Does a Transplant Cost?*. (2010). Available from: <http://www.transplants.org/faq/how-much-does-transplant-cost>
100. United Network for Organ Sharing. *Costs*. (2016). Available from: <http://www.transplantliving.org/before-the-transplant/financing-a-transplant/the-costs/>
101. World health organization, Ke X, Priyanka S, Holly A. *The Determinants of Health Expenditure: A Country-Level Panel Data Analysis*. (2011). Available from: http://www.who.int/health_financing/documents/report_en_11_deter-he.pdf
102. Chemello C, Aguilera M, Cañadas Garre M, Calleja Hernández MA. Pharmacogenetics and pharmacogenomics of chronic kidney disease comorbidities and kidney transplantation. In: Barh D, Dhawan D, Kumar Ganguly N, editors. *Omics for Personalized Medicine*. India: Springer (2013). p. 801–17.
103. Provenzani A, Santeusano A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. *World J Gastroenterol* (2013) 19(48):9156–73. doi:10.3748/wjg.v19.i48.9156
104. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. *Cleve Clin J Med* (2011) 78(4):243–57. doi:10.3949/ccjm.78a.10145
105. Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. *Health Technol Assess* (2010) 14(3):1–157. doi:10.3310/hta14030
106. Berm EJ, de Looft M, Wilffert B, Boersma C, Annemans L, Vegter S, et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. *PLoS One* (2016) 11(1):e0146262. doi:10.1371/journal.pone.0146262
107. van den Akker-van Marle ME, Gurwitz D, Detmar SB, Enzing CM, Hopkins MM, Gutierrez de Mesa E, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. *Pharmacogenomics* (2006) 7(5):783–92. doi:10.2217/14622416.7.5.783
108. Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. *Pharmacoeconomics* (2006) 24(8):767–81. doi:10.2165/00019053-200624080-00004
109. Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. *Am J Gastroenterol* (2005) 100(10):2239–47. doi:10.1111/j.1572-0241.2005.41900.x
110. Thervet E, Lorient MA, Barbier S, Buchler M, Fichoux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. *Clin Pharmacol Ther* (2010) 87(6):721–6. doi:10.1038/clpt.2010.17
111. Ogura S, Jakovljevic M. Health financing constrained by population aging: an opportunity to learn from Japanese experience. *Ser J Exp Clin Res* (2014) 15(4):175–81. doi:10.2478/sjccr-2014-0022
112. Jakovljevic M, Laaser U. Population aging from 1950 to 2010 in seventeen transitional countries in the wider region of south eastern Europe. *SEEJPH* (2015) 3:1–12. doi:10.12908/SEEJPH-2014-42
113. Mihailovic N, Kocic S, Jakovljevic M. Review of diagnosis-related group-based financing of hospital care. *Health Serv Res Manag Epidemiol* (2016) 3:1–8. doi:10.1177/2333392816647892

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Rancic, Dragojevic-Simic, Vavic, Kovacevic, Segrt and Djordjevic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.